Proactive Investors - Run By Investors For Investors

Keystone Bio has 'many avenues' to take its heart disease drug to a larger stage

Peter Nara, CEO of Keystone Bio speaks to Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Keystone Bio is initiating Phase I/II clinical trials for its proprietary bio-therapeutic-drug for heart disease targeting volatile coronary artery plaque and post-event myocardium vulnerability.

View full BIO profile View Profile

Keystone Bio Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use